CancerDrs Find care

Multiple Myeloma clinical trials in District of Columbia

11 actively recruiting multiple myeloma trials at 1 site across District of Columbia.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Industry

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …

Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in District of Columbia:
  • Research Site — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …

Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Sites in District of Columbia:
  • Sibley Memorial Hospital — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06615479
Sites in District of Columbia:
  • Local Institution - 0223 — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants w…

Sponsor: Sanofi
NCT ID: NCT06356571
Sites in District of Columbia:
  • Maryland Oncology Hematology- Site Number : 8400038 — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.

Sponsor: Hackensack Meridian Health
NCT ID: NCT05199311
Sites in District of Columbia:
  • Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Pilot Imaging Study of Leukemia

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, mole…

Sponsor: University of Oklahoma
NCT ID: NCT03633955
Sites in District of Columbia:
  • Children's National Health System — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
  • MedStar Washington Hospital Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Recruiting Network

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Mosaic Trial for Stem Cell Transplant Recipients

The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an…

Sponsor: Northwestern University
NCT ID: NCT06960993
Sites in District of Columbia:
  • Georgetown University School of Medicine — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Recruiting Academic/Other

Cancer Experience Registry (CER) for Cancer Patients and Caregivers

The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys. Study surv…

Sponsor: Cancer Support Community, Research and Training Institute, Philadelphia
NCT ID: NCT02333604
Sites in District of Columbia:
  • Cancer Support Community Research & Training Institute — Washington D.C., District of Columbia
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20